Novo Nordisk Annual Sales Jump on Higher Demand for Obesity Drugs
The Danish maker of Ozempic and Wegovy reported a 25 percent increase in sales to $40.6 billion, but said it expected slower ...
Novo Nordisk’s (NVO) CEO Is Not Worried About Government Price Negotiations
Novo Nordisk (NVO), a pharmaceutical company, isn’t too worried about the U.S. government’s plan to negotiate prices for its ...
Novo Nordisk Outlook Provides Some Welcome Relief
The Danish pharmaceutical company’s blockbuster Wegovy weight-loss drug just missed sales expectations in the fourth quarter ...
Wegovy sales double to boost Novo Nordisk's fourth quarter as growth set to slow
Obesity drug maker Novo Nordisk forecast slower growth this year after Wegovy sales more than doubled in the fourth quarter, ...
Yahoo Finance15d
Novo Nordisk stock pops on phase I data for new weight-loss drug amycretin
A view shows the logo of Novo Nordisk at the company's office in Bagsvaerd, on the outskirts of Copenhagen, Denmark, March 8, 2024. REUTERS/Tom Little//File Photo · Reuters / Reuters The company ...
Novo Nordisk missed its diversity targets last year, and its CEO paid a financial price
Novo Nordisk's CEO took a $1.5 million pay cut in 2024 as the pharma giant's share price tanked and it missed profit and DEI ...
NVO INVESTOR DEADLINE: Novo Nordisk Investors are Alerted to Contact BFA Law before the Imminent March 25 Class Action Deadline
New York, New York-- (Newsfile Corp. - February 7, 2025) - Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against Novo Nordisk (NYSE: NVO) and certain ...
Novo Nordisk Stock Rises as Q4 Wegovy Sales More Than Double
Novo Nordisk's U.S.-listed shares are rising 4% in premarket trading after the Ozempic and Wegovy maker's better-than-estimated quarterly results offset slower 2025 sales growth projections amid ...